These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 2261828)

  • 1. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus.
    Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H
    Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828
    [No Abstract]   [Full Text] [Related]  

  • 2. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis.
    Salvati F; Strippoli P; Barchetti M; Scatizzi A
    Nephron; 1992; 60(3):371. PubMed ID: 1373475
    [No Abstract]   [Full Text] [Related]  

  • 4. The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis.
    Shrivastava D; Rao TK; Sinert R; Khurana E; Lundin AP; Friedman EA
    Am J Kidney Dis; 1995 Jun; 25(6):904-9. PubMed ID: 7771487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 6. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection.
    Inaba M; Okuno S; Kumeda Y; Yamada S; Imanishi Y; Tabata T; Okamura M; Okada S; Yamakawa T; Ishimura E; Nishizawa Y;
    J Am Soc Nephrol; 2007 Mar; 18(3):896-903. PubMed ID: 17267743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant erythropoietin and chronic renal failure.
    Lundin AP
    Hosp Pract (Off Ed); 1991 Apr; 26(4):61-9. PubMed ID: 2010480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utility of recombinant human erythropoietin on the anemia of elderly hemodialysis patients].
    Ueyama H; Nakahashi H; Sawanishi K; Kuze M; Ono T
    Hinyokika Kiyo; 1992 Dec; 38(12):1429-35. PubMed ID: 1288237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemoglobin concentrations in chronic kidney disease.
    Steinbrook R
    Lancet; 2006 Dec; 368(9554):2191-3. PubMed ID: 17189015
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
    Sobota JT
    Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 12. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
    Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
    Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
    Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
    BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Erythropoietin, blood viscosity and hypertension in chronic kidney failure].
    Schaefer RM; Heidland A
    Dtsch Med Wochenschr; 1989 Jun; 114(26):1046-9. PubMed ID: 2661190
    [No Abstract]   [Full Text] [Related]  

  • 15. [Recombinant human erythropoietin and chronic kidney failure: current situation and therapeutic implications].
    Romero González R; Torquet Escuder P
    Med Clin (Barc); 1990 Nov; 95(17):656-9. PubMed ID: 2089205
    [No Abstract]   [Full Text] [Related]  

  • 16. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
    Nikolaev AIu; Klepikov PV; Lashutin SV
    Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
    [No Abstract]   [Full Text] [Related]  

  • 17. [The importance of erythropoietin in the therapy of anemia in patients on chronic hemodialysis].
    von Appen K; Klinkmann H
    Urol Nefrol (Mosk); 1990; (6):69-70. PubMed ID: 2089771
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report.
    Adamson W; Egrie JC; Browne JK; Downing MR; Eschbach W
    Behring Inst Mitt; 1988 Aug; (83):188-92. PubMed ID: 3071336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M
    Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
    [No Abstract]   [Full Text] [Related]  

  • 20. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.